☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Tyvyt
Innovent Reports Results of Tyvyt + Byvasda (biosimilar- bevacizumab) in P-lll ORIENT-32 Study as 1L Treatment for HCC
November 23, 2020
Innovent Report Results of Dual Regimen in P-III ORIENT-32 Study as 1L Therapy for Advanced HCC
September 28, 2020
Lilly and Innovent Report the Global Expansion of their Alliance for Tyvyt (sintilimab)
August 18, 2020
Innovent and Eli Lilly Report sNDA Acceptance of Tyvyt (sintilimab) Combination Regimen as 1L Therapy in Squamous Non-Small Cell L...
August 12, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.